Merus NV 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

7 Apr 2025

MRUS

10-K/A: Merus N.V. Files Amendment to 10-K to Include Insider Trading Compliance Policy

Merus N.V. files an amendment to its annual report on Form 10-K to include its Insider Trading Compliance Policy, which was inadvertently omitted from the original filing.

27 Feb 2025

MRUS

Merus NV

10-K: Merus N.V. Reports Full Year 2024 Financial Results and Provides Business Update

Merus N.V. details its financial performance for 2024 and provides an update on its clinical programs, including zenocutuzumab, petosemtamab, and MCLA-129.

28 Feb 2024

MRUS

Merus NV

10-K: Merus N.V. Reports Full Year 2023 Results, Outlines Key Clinical Milestones

Merus N.V., a clinical-stage oncology company, released its 2023 annual report, highlighting progress in its multispecific antibody programs and providing a financial overview.